sibrafiban

sibrafiban

Xubix™ Cardiology A 'superaspirin' GP IIb/IIIa receptor antagonist used to prevent post coronary-angioplasty coagulation
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
The secondary analysis data from SYMPHONY I and II (Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post Acute Coronary Syndrome) were presented at the annual scientific sessions of the American Heart Association.
Statins don't cut postevent mortality rate at 1 year. (Symphony Trials)
(21.) Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes.
Elementos para la valoracion y el uso practico de los ensayos clinicos: parte I: estructura basica y terminologia usual
The oral glycoprotein inhibitor sibrafiban is no better than aspirin in secondary prevention of major ischemic events, even though it is the more potent inhibitor of platelet aggregation, reported Dr.
Oral Glycoprotein Inhibitor

Medical browser ?
Full browser ?